Mark Page

Arstasis, Inc. develops and manufactures medical devices for femoral catheterizations. It offers AXERA access device, a vascular access device that is used in patients undergoing diagnostic femoral artery catheterization procedures using 5F or 6F introducer sheaths. The company was founded in August 2004 by D. Bruce Modesitt and is headquartered in Fremont, CA.

FlowCardia, Inc. designs, develops and manufactures endovascular devices. It offers flowmate Injector to optimize the performance of crosser cto recanalization and crosser catheter, a minimally-invasive endovascular device. The firm also provides portfolio of catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. The company was founded by Henry Nita and Erik T. Engelson in 2001 and is headquartered in Sunnyvale, CA.

Arstasis, Inc. develops and manufactures medical devices for femoral catheterizations. It offers AXERA access device, a vascular access device that is used in patients undergoing diagnostic femoral artery catheterization procedures using 5F or 6F introducer sheaths. The company was founded in August 2004 by D. Bruce Modesitt and is headquartered in Fremont, CA.

Arstasis, Inc. develops and manufactures medical devices for femoral catheterizations. It offers AXERA access device, a vascular access device that is used in patients undergoing diagnostic femoral artery catheterization procedures using 5F or 6F introducer sheaths. The company was founded in August 2004 by D. Bruce Modesitt and is headquartered in Fremont, CA.

Arstasis, Inc. develops and manufactures medical devices for femoral catheterizations. It offers AXERA access device, a vascular access device that is used in patients undergoing diagnostic femoral artery catheterization procedures using 5F or 6F introducer sheaths. The company was founded in August 2004 by D. Bruce Modesitt and is headquartered in Fremont, CA.

FlowCardia, Inc. designs, develops and manufactures endovascular devices. It offers flowmate Injector to optimize the performance of crosser cto recanalization and crosser catheter, a minimally-invasive endovascular device. The firm also provides portfolio of catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. The company was founded by Henry Nita and Erik T. Engelson in 2001 and is headquartered in Sunnyvale, CA.

FlowCardia, Inc. designs, develops and manufactures endovascular devices. It offers flowmate Injector to optimize the performance of crosser cto recanalization and crosser catheter, a minimally-invasive endovascular device. The firm also provides portfolio of catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. The company was founded by Henry Nita and Erik T. Engelson in 2001 and is headquartered in Sunnyvale, CA.

FlowCardia, Inc. designs, develops and manufactures endovascular devices. It offers flowmate Injector to optimize the performance of crosser cto recanalization and crosser catheter, a minimally-invasive endovascular device. The firm also provides portfolio of catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. The company was founded by Henry Nita and Erik T. Engelson in 2001 and is headquartered in Sunnyvale, CA.

Arstasis, Inc. develops and manufactures medical devices for femoral catheterizations. It offers AXERA access device, a vascular access device that is used in patients undergoing diagnostic femoral artery catheterization procedures using 5F or 6F introducer sheaths. The company was founded in August 2004 by D. Bruce Modesitt and is headquartered in Fremont, CA.

Arstasis, Inc. develops and manufactures medical devices for femoral catheterizations. It offers AXERA access device, a vascular access device that is used in patients undergoing diagnostic femoral artery catheterization procedures using 5F or 6F introducer sheaths. The company was founded in August 2004 by D. Bruce Modesitt and is headquartered in Fremont, CA.

Arstasis, Inc. develops and manufactures medical devices for femoral catheterizations. It offers AXERA access device, a vascular access device that is used in patients undergoing diagnostic femoral artery catheterization procedures using 5F or 6F introducer sheaths. The company was founded in August 2004 by D. Bruce Modesitt and is headquartered in Fremont, CA.

FlowCardia, Inc. designs, develops and manufactures endovascular devices. It offers flowmate Injector to optimize the performance of crosser cto recanalization and crosser catheter, a minimally-invasive endovascular device. The firm also provides portfolio of catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. The company was founded by Henry Nita and Erik T. Engelson in 2001 and is headquartered in Sunnyvale, CA.